Cargando…
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
The pace of innovation of multiple myeloma therapy in recent years is remarkable with the advent of monoclonal antibodies and the approval of novel agents with new mechanisms of action. Emerging therapies are on the horizon for clinical approval with significant implications in extending patient sur...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299593/ https://www.ncbi.nlm.nih.gov/pubmed/34301270 http://dx.doi.org/10.1186/s13045-021-01109-y |